Overview
Hemas is a diversified Sri Lankan group spanning healthcare, consumer brands, mobility, leisure, travel, logistics and maritime activities. Healthcare is its largest reported segment exposure, alongside consumer businesses including Atlas and other home and personal-care brands.
The main strategic change is its first overseas acquisition: Hemas reported on 18 August that it acquired a 75% stake in Kenya's Twiga Stationers and Printers through Atlas Axillia. The deal opens an East African consumer platform, but the reported terms do not disclose the acquired business's earnings, so its contribution cannot yet be sized.
Price performance
At LKR 30.90 on 24 September 2026, the share had fallen 5.2% over three months against a 5.3% ASPI decline, then gained 6.9% over six months versus 2.1% for the index. Its recent relative performance has therefore been broadly market-like in the shorter period and ahead of the index over six months.
The price sits 35.3% of the way through its 52-week range, closer to the low than the high. Sixty-day volatility was 42.8% below its own one-year norm and 20-day volume was 8.9% below the prior 60-day pace, indicating quieter recent trading in both price movement and activity.
The three-year record contains three falls of 15% or more, the deepest 24%, which took seven months to recover. Median daily turnover was LKR 6.6 million; a LKR 1 million order is about 15% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
At 10.7 times earnings, the share asks for about LKR 10.70 for every LKR 1 of trailing profit, below the diversified-holdings median of 14.47 times and at the 38th percentile of 17 peers with P/E data. Its P/B of 1.66 means LKR 1.66 for each LKR 1 of net assets, above the sector median of 1.20 and at the 70th percentile of 21 peers. The higher P/B is partly reconciled by a 15.5% trailing return on equity, which is the profitability generated from shareholders' capital.
The 3.2% dividend yield exceeds the sector median of 2.7%, while dividends per share rose from LKR 0.68 in FY2024 to LKR 0.90 in FY2025 and LKR 1.00 in FY2026. This was covered 2.89 times by trailing earnings, so less than half of reported profit was distributed.
The two valuation measures give different messages against Hemas's own record: P/E is cheaper than 68% of days since January 2019, while P/B is more expensive than 72% of days since January 2019. A buyer at this price is relying little on the latest June quarter, which supplied 10.8% of trailing EPS; at its year-ago net margin, P/E would be 10.5 times rather than 10.7 times.
News and sentiment
Direct coverage was normal rather than sparse: 16 material articles appeared in the past 90 days, split between eight positive, seven negative and one neutral. Coverage was unusually quiet in the latest 30 days, with one article against Hemas's monthly baseline of 2.5.
The material news centred on the Kenyan acquisition, reported on 18 August, and June-quarter cost pressure reported on 7 August. The LKR 0.75 FY2026 final dividend went ex on 30 June 2026, so a buyer today does not receive it.
Financials
June-quarter revenue rose 0.9% year-on-year, but operating profit fell 21.1% and net profit fell 15.7% to LKR 1.1 billion. Gross margin was 30.4% versus 30.1% a year earlier, operating margin was 5.7% versus 7.2%, and net margin was 3.7% versus 4.4%. Gross margin was among Hemas's best June readings, at second of seven, while operating and net margins were middling at fifth of seven.
June has been the weakest quarter for operating margin on average over the five complete years on record, so the low operating-margin print should be judged against prior Junes rather than stronger quarters. Even so, the year-on-year margin contraction is a real pressure point. Below-the-line costs absorbed LKR 569 million, down from LKR 809 million a year earlier, which softened the decline in net profit relative to operating profit.
For audited FY2026, revenue rose 8.0% to LKR 127.4 billion and net profit rose 11.4% to LKR 9.3 billion. June 2026 total equity was LKR 56.4 billion, up from LKR 49.4 billion a year earlier, while the balance sheet used the current share count of 3.0 billion ordinary shares. The 1:5 share subdivision took effect in May 2025, so older per-share figures are not directly comparable without the stated restatement.
Risks
The principal operating risk is margin pressure across a broad consumer and healthcare portfolio. June operating margin fell from 7.2% to 5.7%, and the company attributed the quarter's weaker earnings to cost escalation, distribution costs and rupee depreciation in reporting published on 7 August.
The balance sheet is a mitigating factor rather than the main risk. At March 2026, debt was LKR 6.1 billion against LKR 17.8 billion of cash, gearing was 10.8% of owners' equity, and operating profit covered interest 13.8 times. The current ratio was 1.72 times, meaning LKR 1.72 of short-term assets, including inventory and customer receivables, for each LKR 1 of bills due within a year. Annual operating cash flow equalled 0.83 times operating profit, so not all accounting profit arrived as cash.
Healthcare represents 62% of reported segment revenue. The sector backdrop includes expanding public healthcare capacity and hospital infrastructure plans, but the available data does not establish a direct effect on Hemas's hospitals or pharmaceutical operations. Consumer activity also faces purchasing-power and energy-cost pressure in the broader backdrop.
Outlook
As at 24 September 2026, the next defining event is the interim quarter ending 30 September 2026, expected to be filed between 6 and 14 November. It will show whether the June margin compression persisted beyond Hemas's structurally weakest operating-margin quarter and whether the Kenyan acquisition has begun to affect the group.
The current data cannot quantify Twiga's earnings contribution or integration costs. The next filing is therefore more informative than the acquisition headline: it can distinguish a broader margin issue from a June-quarter outcome concentrated in the group's historically weakest operating-margin period.